Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of guselkumab in fistulizing perianal Crohn's disease
2021-000491-10Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Guselkumab with Placebo (2 arms). Primary endpoint: Combined fistula remission at Week 24. Started Apr 2022; status: active.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2021-000491-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000491-10.